Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK/Ranbaxy Deal Gives Indian Firm Greater Development Charge

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline and Ranbaxy Laboratories broadened a 2003 agreement to give the Indian company new responsibilities for developing drug candidates, the companies announced Feb. 6

You may also be interested in...

GSK Shopping Spree Continues With Praecis Acquisition

Latest deal could bring GSK’s total price tag for December to almost $4 billion.

GSK Signs Deal With Epix For GPCR Candidates

Epix will be eligible to earn milestones of $1.2 billion based on development and commercialization of four programs, including a Phase II Alzheimer’s molecule.

GSK’s Center Of Excellence For External Drug Discovery Head Maxine Gowen: An Interview With “The Pink Sheet” DAILY

Company's approach to biotech deals differs from big pharma competitors, Gowen says.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts